Pemetrexed
Pemetrexed
Klass : C!
Visa all info
Skriv ut
Kontakta oss
Produkter
Visa alla produkter
ALIMTA, Armisarte, Pemetrexed Accord, Pemetrexed EVER Pharma, Pemetrex......
ALIMTA, Armisarte, Pemetrexed Accord, Pemetrexed EVER Pharma, Pemetrexed Fresenius Kabi, Pemetrexed Hexal, Pemetrexed Mylan, Pemetrexed Pfizer, Pemetrexed Reig Jofre, Pemetrexed STADA, Pemetrexed ZentivaATC-koder
L01BA04
L01BA04Substanser
Visa alla substanser
pemetrexed, pemetrexeddinatrium-2,5-hydrat, pemetrexeddinatriumheptahy......
pemetrexed, pemetrexeddinatrium-2,5-hydrat, pemetrexeddinatriumheptahydrat, pemetrexedmonohydratSammanfattning
Kvinnor har visats ha bättre effekt av pemetrexed-baserad kombinationsbehandling än män. Dock är kvinnor mer benägna att drabbas av illamående och kräkningar. Pemetrexedbehandling hos såväl kvinnor som män kan orsaka fosterskada och ska undvikas till flickor och kvinnor som kan tänkas bli gravida om inte en effektiv preventivmetod ska användas.
Kvinnor har visats ha bättre effekt av pemetrexed-baserad kombinationsbehandling än män. Dock är kvinnor mer benägna att drabbas av illamående och kräkningar. Pemetrexedbehandling hos såväl kvinnor som män kan orsaka fosterskada och ska undvikas till flickor och kvinnor som kan tänkas bli gravida om inte en effektiv preventivmetod ska användas.Background
The incidence of lung cancer has decreased among men since the 1980s but has increased significantly among women, which reflects women's changing smoking habits. Now the proportion of smoking women is greater than the proportion of smoking men. In Sweden lung cancer made up 6.1% of all yearly cases of cancer, year 2016. The incidence was higher among women (6.8%, n=2067), compared to men (5.4%, n=1824) [1]. Visa hela bakgrundstexten
Generally, women mount stronger innate and adaptive immune responses than men [2]. Women with lung cancer have a more favorable survival compared to men [3]. The 5-year survival is 24 percent among women, and 17 percent among men in Sweden [1].
Since chemotherapeutic agents share some adverse effects, evaluation of a particular agent’s sex-related adverse effects during combination chemotherapy is complicated. Another factor that complicates the evaluation of chemotherapeutic treatments’ effect is a poorer prognosis in men compared to women of most oncologic diseases that affect both sexes [4, 5]. For instance, and related to this particular context, female sex is a favorable pr......
Försäljning på recept
Visa hela försäljning på recept
Läkemedel innehållande pemetrexed (ATC-kod L01BA04) används huvudsakligen på sjukhus och därför saknas könsuppdelade användningsdata [19].
Referenser
Visa referenser
Socialstyrelsen. Cancer i siffror 2018. Socialstyrelsen [www]. [updated 2018-06-10, cited 2020-10-01].
Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16(10):626-38.
Vera Regitz-Zagrosek. Sex and Gender Differences in Pharmacology. Springer-Verlag Berlin Heidelberg; 2012.
Radkiewicz, C. Sex differences in cancer risk and survival. [dissertation]. Dept of Medical Epidemiology and Biostatistics: Karolinska Institutet; 2019.
Edgren G, Liang L, Adami HO, Chang ET. Enigmatic sex disparities in cancer incidence. Eur J Epidemiol. 2012;27(3):187-96.
de Perrot M, Licker M, Bouchardy C, Usel M, Robert J, Spiliopoulos A. Sex differences in presentation, management, and prognosis of patients with non-small cell lung carcinoma. J Thorac Cardiovasc Surg. 2000;119(1):21-6.
Ferguson MK, Skosey C, Hoffman PC, Golomb HM. Sex-associated differences in presentation and survival in patients with lung cancer. J Clin Oncol. 1990;8(8):1402-7.
Singh S, Parulekar W, Murray N, Feld R, Evans WK, Tu D et al. Influence of sex on toxicity and treatment outcome in small-cell lung cancer. J Clin Oncol. 2005;23(4):850-6.
Visbal AL, Williams BA, Nichols FC, Marks RS, Jett JR, Aubry MC et al. Gender differences in non-small-cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997 and 2002. Ann Thorac Surg. 2004;78(1):209-15; discussion 215.
Hsu LH, Chu NM, Liu CC, Tsai SY, You DL, Ko JS et al. Sex-associated differences in non-small cell lung cancer in the new era: is gender an independent prognostic factor?. Lung Cancer. 2009;66(2):262-7.
Afanasjeva J, Hui RL, Spence MM, Chang J, Schottinger JE, Millares M et al. Identifying Subsequent Therapies in Patients with Advanced Non-Small Cell Lung Cancer and Factors Associated with Overall Survival. Pharmacotherapy. 2016;36(10):1065-1074.
Mencoboni M, Filiberti RA, Taveggia P, Grosso F, Pasello G, Del Corso L et al. Clinical Features and Treatment Outcome of Malignant Pleural Mesothelioma. Oncol Res Treat. 2017;40(6):364-369.
Liu M, Luo N, Fang Z, Liu Q, Yi F, Wei Y et al. The efficacy and toxicity of maintenance therapy with bevacizumab plus pemetrexed versus bevacizumab/pemetrexed alone for stage IIIB/IV nonsquamous non-small cell lung cancer: A meta-analysis of randomized controlled trials. J Clin Pharm Ther. 2022;47(2):157-167.
Weiss GJ, Rosell R, Fossella F, Perry M, Stahel R, Barata F et al. The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer. Ann Oncol. 2007;18(3):453-60.
Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, Chinnery LW et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines American Society of Clinical Oncology. J Clin Oncol. 1999;17(9):2971-94.
Hayashi T, Shimokawa M, Matsuo K, Iihara H, Kawada K, Nakano T et al. Chemotherapy-induced nausea and vomiting (CINV) with carboplatin plus pemetrexed or carboplatin plus paclitaxel in patients with lung cancer: a propensity score-matched analysis. BMC Cancer. 2021;21(1):74.
Shimokawa M, Haratake N, Takada K, Toyokawa G, Takamori S, Mizuki F et al. Combination Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients with NSCLC Receiving Carboplatin-Based Chemotherapy. Cancer Manag Res. 2022;14:2673-2680.
Pemetrexed Accord (pemetrexed). Summary of Product Characteristics. European Medicines Agency [updated 2022-08-01, cited 2023-04-04]
Conise (INSIKT). Kalmar: eHälsomyndigheten. 2018 [cited 2021-11-18.]
- Socialstyrelsen. Cancer i siffror 2018. Socialstyrelsen [www]. [updated 2018-06-10, cited 2020-10-01].
- Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16(10):626-38.
- Vera Regitz-Zagrosek. Sex and Gender Differences in Pharmacology. Springer-Verlag Berlin Heidelberg; 2012.
- Radkiewicz, C. Sex differences in cancer risk and survival. [dissertation]. Dept of Medical Epidemiology and Biostatistics: Karolinska Institutet; 2019.
- Edgren G, Liang L, Adami HO, Chang ET. Enigmatic sex disparities in cancer incidence. Eur J Epidemiol. 2012;27(3):187-96.
- de Perrot M, Licker M, Bouchardy C, Usel M, Robert J, Spiliopoulos A. Sex differences in presentation, management, and prognosis of patients with non-small cell lung carcinoma. J Thorac Cardiovasc Surg. 2000;119(1):21-6.
- Ferguson MK, Skosey C, Hoffman PC, Golomb HM. Sex-associated differences in presentation and survival in patients with lung cancer. J Clin Oncol. 1990;8(8):1402-7.
- Singh S, Parulekar W, Murray N, Feld R, Evans WK, Tu D et al. Influence of sex on toxicity and treatment outcome in small-cell lung cancer. J Clin Oncol. 2005;23(4):850-6.
- Visbal AL, Williams BA, Nichols FC, Marks RS, Jett JR, Aubry MC et al. Gender differences in non-small-cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997 and 2002. Ann Thorac Surg. 2004;78(1):209-15; discussion 215.
- Hsu LH, Chu NM, Liu CC, Tsai SY, You DL, Ko JS et al. Sex-associated differences in non-small cell lung cancer in the new era: is gender an independent prognostic factor?. Lung Cancer. 2009;66(2):262-7.
- Afanasjeva J, Hui RL, Spence MM, Chang J, Schottinger JE, Millares M et al. Identifying Subsequent Therapies in Patients with Advanced Non-Small Cell Lung Cancer and Factors Associated with Overall Survival. Pharmacotherapy. 2016;36(10):1065-1074.
- Mencoboni M, Filiberti RA, Taveggia P, Grosso F, Pasello G, Del Corso L et al. Clinical Features and Treatment Outcome of Malignant Pleural Mesothelioma. Oncol Res Treat. 2017;40(6):364-369.
- Liu M, Luo N, Fang Z, Liu Q, Yi F, Wei Y et al. The efficacy and toxicity of maintenance therapy with bevacizumab plus pemetrexed versus bevacizumab/pemetrexed alone for stage IIIB/IV nonsquamous non-small cell lung cancer: A meta-analysis of randomized controlled trials. J Clin Pharm Ther. 2022;47(2):157-167.
- Weiss GJ, Rosell R, Fossella F, Perry M, Stahel R, Barata F et al. The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer. Ann Oncol. 2007;18(3):453-60.
- Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, Chinnery LW et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines American Society of Clinical Oncology. J Clin Oncol. 1999;17(9):2971-94.
- Hayashi T, Shimokawa M, Matsuo K, Iihara H, Kawada K, Nakano T et al. Chemotherapy-induced nausea and vomiting (CINV) with carboplatin plus pemetrexed or carboplatin plus paclitaxel in patients with lung cancer: a propensity score-matched analysis. BMC Cancer. 2021;21(1):74.
- Shimokawa M, Haratake N, Takada K, Toyokawa G, Takamori S, Mizuki F et al. Combination Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients with NSCLC Receiving Carboplatin-Based Chemotherapy. Cancer Manag Res. 2022;14:2673-2680.
- Pemetrexed Accord (pemetrexed). Summary of Product Characteristics. European Medicines Agency [updated 2022-08-01, cited 2023-04-04]
- Conise (INSIKT). Kalmar: eHälsomyndigheten. 2018 [cited 2021-11-18.]
Uppdaterat
Litteratursökningsdatum: 4/4/2023
Litteratursökningsdatum: 4/4/2023